发明公开
EP2226396A1 Gene expression markers for response to EGFR inhibitor drugs
审中-公开
Genexpressionsmarkerfürdie Antwort auf EGFR Inhibitor Arzneistoffe
- 专利标题： Gene expression markers for response to EGFR inhibitor drugs
- 专利标题（中）： Genexpressionsmarkerfürdie Antwort auf EGFR Inhibitor Arzneistoffe
-
申请号： EP10158352.4申请日： 2004-05-28
-
公开(公告)号： EP2226396A1公开(公告)日： 2010-09-08
- 发明人: Baker, Joffre B. , Shak, Steve , Agus, David , Natale, Ronald
- 申请人： Genomic Health, Inc. , Cedars-Sinai Medical Center
- 申请人地址： 301 Penobscot Drive Redwood City, CA 94063 US
- 专利权人： Genomic Health, Inc.,Cedars-Sinai Medical Center
- 当前专利权人： Genomic Health, Inc.,Cedars-Sinai Medical Center
- 当前专利权人地址： 301 Penobscot Drive Redwood City, CA 94063 US
- 代理机构： Tollett, Ian
- 优先权： US474908P 20030530
- 主分类号： C12Q1/68
- IPC分类号： C12Q1/68
摘要：
The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
信息查询
